Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC

/in , , , /by

Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. ​Eighty-four patients enrolled […]

Read more

UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer

/in , , , /by

The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]

Read more

Early Results From a Phase 1 Trial for MRT-2359 Plus Enzalutamide in mCRPC

/in , , , /by

MRT-2359 is a daily pill that destroys certain cancer-driving proteins, including the androgen receptor (AR), MYC, and Cyclin D1, by blocking a key step in how cells read genetic instructions. This approach targets metastatic castration-resistant prostate cancer (mCRPC), where AR mutations in the ligand-binding domain (LBD) allow tumors to grow despite hormone-blocking drugs like enzalutamide. […]

Read more

BRCAAway OS Update: Abiraterone + Olaparib Extends Survival by 5 Years in HRRm mCRPC

/in , , /by

The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic […]

Read more

UPDATE: SECuRE Trial, Another Complete Responder

/in , , /by

A striking new update from the ongoing SECuRE trial has revealed yet another participant achieving undetectable PSA levels alongside a completely negative PSMA PET scan, underscoring the potential of 67Cu-SAR-bisPSMA in advanced prostate cancer treatment. This 76-year-old patient, facing progressive metastatic castration-resistant prostate cancer (mCRPC) 15 years after initial diagnosis, started with a baseline PSA […]

Read more

SHR-4394: Phase 1/2 Trial Explores PSMA-Targeted ADC Combination Therapies in Prostate Cancer

/in , , , /by

A Phase 1/2 clinical trial (NCT07407283) is investigating SHR-4394, a novel PSMA-targeted antibody-drug conjugate (ADC), in combination with other anticancer treatments for patients with advanced prostate cancer. SHR-4394 is designed to recognize prostate-specific membrane antigen (PSMA), a protein commonly expressed on prostate cancer cells, and deliver a cytotoxic payload directly to the tumor. Unlike PSMA-targeted […]

Read more

Phase 1/2 ACRES Trial: Pioneering 225Ac-rhPSMA-10.1 for Post-Lutetium mCRPC

/in , , , /by

The ACRES (ACT-RESoLUTE) trial represents a promising step forward in targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC), focusing on Actinium-225-labeled radiohybrid PSMA-10.1 (225Ac-rhPSMA-10.1) in patients who have largely progressed after Lutetium-177 PSMA therapy. This multi-site, open-label Phase 1/2 study addresses an urgent need in advanced prostate cancer, where effective post-Lu-PSMA options remain limited […]

Read more

EBNK-001: Pioneering Off-the-Shelf NK Cell Therapy for Solid Tumors

/in , , , /by

EBNK-001 represents a promising advancement in cancer immunotherapy as an “off-the-shelf” allogeneic natural killer (NK) cell product designed for multi-dose administration in patients with advanced solid tumors. Unlike autologous therapies that require individual patient cell harvesting and processing, EBNK-001 leverages healthy donor-derived NK cells, enabling immediate availability without lengthy manufacturing delays. This off-the-shelf approach addresses […]

Read more

FDA Clears Phase 2b Trial of Teverelix in Advanced Prostate Cancer Patients at High Cardiovascular Risk

/in , , /by

A new phase 2b clinical trial has received FDA “study may proceed” clearance for teverelix, a long‑acting GnRH antagonist being evaluated in men with advanced prostate cancer who are at high cardiovascular risk. The trial is designed to test a dose‑optimization regimen of teverelix over a 22‑week treatment period, with the primary goal of confirming […]

Read more

SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC)

/in , , , /by

A  first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]

Read more